AB Science S.A. (AB.PA) Stock Analysis & Winston Score

AB Science is a French pharmaceutical company that researches and develops drugs targeting a type of protein called kinases, which play a role in diseases like cancer, inflammation, and neurological conditions. Its main product is masitinib, a drug it has tested across multiple diseases including ALS (a serious nerve disease), mastocytosis (a rare immune disorder), and certain cancers. The company sells to patients through hospitals and specialist doctors, primarily in Europe. AB Science earns revenue mainly from drug sales and licensing agreements, though it remains a small, early-stage company with a market value around $100 million. It is headquartered in Paris and operates mostly in Europe, with some clinical trial activity elsewhere. The company has spent years trying to get masitinib approved for additional conditions, but its deeply negative operating margin shows it spends far more than it earns, meaning regulatory approval of masitinib in a major indication like ALS is both its biggest growth opportunity and its most critical risk.